



What Sets Us Apart?

- Our strong technical expertise and understanding of the legal and regulatory environment.
- Our proprietary in-house data and analytics, supporting a more efficient IP risk assessment.
- Our proactive and solution-oriented approach.

Risk Appetite Overview

SUBSEGMENT	EXAMPLE PRODUCT & SERVICE TYPES	IP RISK APPETITE
MedTech	Class 1, 2 and 3 Medical Devices Implants/Non-Implants Diagnostics Durable Medical Equipment	Strong appetite
Pharmaceuticals*	Generic OTC Drugs New Chemical Entities New Formulations	Moderate to strong appetite
	Biologics Biosimilars Generic Rx	Weak appetite
Nutraceuticals (Dietary Supplements)	Standalone or proprietary blends of: Amino Acids Herbs Minerals Vitamins	Strong appetite
Biotechnology Suing Ter	Clinical/Test Services Laboratory Equipment Platform Technology for Drug Production Research Use Only Reagents & Assays	Moderate to strong appetite

Other Considerations

Some products may not fall neatly into these categories such as:

- API Manufacturers
- Component/Sub-Assemblers
- Non-Owners (e.g. contract manufacturers, labelers/relabelers, packagers/re-packagers)

A prospective insured's ownership and control of its products, its operational activities relating to its products, or the stage of product development may modify its IP risk exposure and our risk appetite.

Maximum Line Size

Any One Risk US\$20m

Key contact

Chris Sclimenti PhD, JD Senior Underwriter (Life Sciences) csclimenti@archinsurance.com +1 858 361 3052

Together



Life Sciences Subsegments

At Arch, we view Life Sciences in four general subsegments:

MedTech:

Primarily medical devices, which range from tongue suppressors to orthopedic implants to pacemakers.

Pharmaceuticals*:

Biologics: large, complex molecules (e.g., an injectable protein).

Biosimilars: a biosimilar drug to the innovator's referenced biologic.

Generic OTC Drugs: small molecule drugs that have existed for a long time, which have been assigned a "monograph" for their labeling.

Generic Rx: generic small molecule drugs that are bioequivalent to the original (referenced) drug, which require a prescription.

New Chemical Entities: novel, small molecule drugs.

New Formulations: often a well-known small molecule to form an enhanced version of the product (e.g., an extended-release tablet).

Nutraceuticals (Dietary Supplements):

Products such as amino acids, herbs, minerals and vitamins that supplement health. They are regulated under the umbrella of "food" by the FDA.

Biotechnology:

Products and services that are not FDA regulated as a drug, medical device, or dietary supplement. This ranges from simple laboratory supplies such as plasticware and pipettors to cell imaging equipment to nucleic acid purification and analysis services.

*No coverage for Hatch-Waxman, Biologics Price Competition and Innovation Act (BPCIA), or foreign equivalent litigation.

for more information on Arch Intangible Assets

Click or scan the QR Code



Pursuing Better Together®

Pursuing Better Together encapsulates how we always aspire to do business at Arch Insurance.

It is an approach that is based on collaboration, responsiveness and a genuine commitment to continually raising the bar.

It is our promise to our brokers, colleagues and other partners to:

- Listen, share insights and work together to deliver informed solutions.
- Build trusting, respectful and responsive relationships.
- Understand your goals and explore possibilities together.

Arch Insurance International

10 Fenchurch Avenue, London, EC3M 5BN www.archinsurance.com/international

- in linkedin.com/company/arch-insurance-europe
- X @ArchInsInt
- slipcase.com/company/arch-insurance
- vimeo.com/archinsurance